A new practice-management editorial argues that the long-dominant ASC model is showing cracks:• Professional fees for colonoscopy have dropped >40% since 2001 • Facility profits are increasingly captured by national ASC owners • Anesthesia costs and staffing shortages continue to squeeze margins With Medicare proposing +14% payment for office-based endoscopy in 2026 (and –7% for ASC settings), GI groups are re-evaluating where their future growth comes from. Leaders like Dr. Lawrence Kosinski say office suites can restore control, autonomy, and value-based agility — while maintaining safety and patient experience. The full article breaks down the financial inflection point, state payer…
Author: Abhay Panchal
Abbott has announced a $23B deal to acquire Exact Sciences, maker of the leading at-home colorectal cancer test used more than 16 million times since launch. Analysts are calling it one of the boldest medtech moves of the decade—a direct bet on the future of cancer diagnostics. Why this matters:• Abbott is doubling its diagnostics market opportunity, from $60B to $120B • Cologuard’s growth could accelerate dramatically through international expansion • Exact’s pipeline (MRD, liquid biopsies, genomic profiling) gives Abbott a foothold across diagnosis → treatment selection → recurrence monitoring Some experts see a smart offensive play. Others question whether…
A breakthrough from Chinese researchers may one day replace colonoscopies with a glowing, bacteria-powered pill. In a new ACS Sensors study, scientists engineered a tiny capsule containing magnetized, heme-sensing bacteria that light up when they detect intestinal bleeding — a hallmark of colitis and other GI diseases. After traveling through the gut, the pill’s biosensors can be retrieved from stool in minutes, and the intensity of their glow reflects disease severity. Early mouse data showed strong accuracy, no safety concerns, and the potential to diagnose gut inflammation without scopes, sedation, or bowel prep. It’s still early-stage science — but if…
A first-of-its-kind JAMA Oncology study is shedding new light on one of the biggest mysteries in GI medicine: why colorectal cancer is rising so sharply in young adults. Researchers followed more than 29,000 women for 13 years and found that those eating the most ultraprocessed foods — especially packaged breads, breakfast items, sauces, and sweetened drinks — had a 45% higher risk of developing early precancerous colorectal adenomas by age 50. The findings stop short of proving causation, but they point to a troubling pattern: UPFs may accelerate the classic adenoma-to-carcinoma pathway, potentially via microbiome disruption, chronic inflammation, and altered…
Roche is moving aggressively into multi-cancer screening outside the U.S. with a new deal to commercialize Freenome’s kitted blood-based CRC and multi-cancer tests in international markets. The agreement includes a $75M equity investment and potential milestones that push the total value past $200M. The partnership also gives Freenome access to Roche’s Axelios sequencing platform — a high-speed NGS system Roche hopes will become a “clinical box” for decentralized cancer screening. Analysts say it doesn’t threaten Illumina yet, but signals Roche’s long-term push into liquid biopsy infrastructure.
A new editorial in JGH Open takes a close look at GastroGPT, a specialty-trained LLM built specifically for gastroenterology. Trained on 1.2M GI-specific tokens — including guidelines, peer-reviewed literature, and 10,000 synthetic vignettes — the model outperformed general LLMs (GPT-4, Bard, Claude) across six of seven clinical tasks, from history-taking to referral decisions to patient education. Early results are impressive: in simulated IBD, endoscopy, and hepatology cases, GastroGPT scored 8.1/10, with strong reproducibility across case complexity. But the authors also flag real-world limitations — simulated datasets, specialty-biased training, and the need for comparisons with purpose-built medical AI models.
Steward Health Care’s collapse has become the case study for how private equity can destabilize hospital systems — and what happens when regulators are asleep at the wheel. This piece traces how a struggling Catholic system morphed into a PE-backed national chain burdened by sale-leasebacks, lawsuits, shuttered hospitals, and one very visible CEO lifestyle, then shows how the fallout is now reshaping state and federal oversight of PE in healthcare.
With reimbursements falling and costs climbing, more independent physicians are asking: Do we partner, sell, or double down on staying solo? This piece lays out 10 strategic paths — from private equity and family offices to CINs, MSOs, health system deals, and “stay independent but scale up” — along with practical due-diligence questions on culture, debt, and “income repair.” If you’re rethinking your practice’s future, this is a roadmap worth studying.
New research is raising eyebrows in GI oncology. A large real-world analysis of nearly 7,000 colon cancer patients found that those on GLP-1 drugs had less than half the 5-year mortality of non-users — with the strongest benefits seen in patients with severe obesity. The signal persisted even after adjusting for disease severity, demographics, and tumor markers, hinting that GLP-1s may be doing more than improving metabolism. Patients on these therapies also had fewer late cardiovascular events and fewer indicators of advancing cancer. Experts call the findings “intriguing and promising,” but caution that randomized trials are essential before GLP-1s can…
A major infusion-care shakeup is underway. Shore Capital Partners has merged Reliant Healthcare and Care Fusion Rx to create a nationwide infusion therapy platform spanning home and ambulatory centers — with meaningful implications for GI patients on biologics, IVIG, and chronic infusion regimens. The new entity blends Reliant’s Southern U.S. footprint with Care Fusion’s West Coast strength in complex therapies, aiming to expand access, streamline coordination with physicians, and accelerate growth through new centers and acquisitions. With leadership from industry veterans and backing from a $14B private equity firm, the platform signals a push toward more scalable, patient-centric infusion delivery.